Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View

Dr. Monica Bertagnolli

Surgical Oncology · Harvard Medical School

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.

    Sep 20, 2025DOI: 10.1245/s10434-025-18307-4Journal ArticleASO

    Written by: Sasha R DouglasSamantha M ThomasAstrid Botty van den BrueleTon WangKendra M ParrishLaura H RosenbergerJennifer K PlichtaMaggie L DiNomeAkiko Chiba

    Find these authors on Roon

    JP
    Dr. Jennifer Plichta
    Breast Surgical Onc · Duke University

    METHODS

    Adult patients (age ≥ 18 years) diagnosed with clinical T1–T4c, N0–3, ER+/HER2− nonmetastatic breast cancer were selected from the National Cancer Database (NCDB) from the Fall 2023 data release. The NCDB includes data from > 1500 Commission on Cancer accredited hospitals and captures > 80% of patients diagnosed with breast cancer each year.7,8 Patients who did not undergo mastectomy or lumpectomy and those who received neoadjuvant chemotherapy or neoadjuvant radiation therapy were excluded, as were those with missing/unknown chemotherapy or radiation receipt or timing data. Patients with missing/unknown pathologic T- or N-category were excluded, along with patients with missing/unknown endocrine therapy receipt or surgery timing. Patients were categorized into two groups: those who received NET and those who underwent surgery first. The start of endocrine treatment was defined by the NCDB on the basis of the North American Association of Central Cancer Registries (NAACCR) data dictionary, which reads: “Date of initiation for hormone therapy that is part of the first course of treatment.” Data were limited to patients diagnosed in 2019–2021 to examine trends prepandemic (2019), during the pandemic (2020), and tail-end-pandemic (2021).Patient characteristics were summarized with N (%) for categorical variables and median (interquartile range, IQR) for continuous variables. Differences were compared with chi-square and t-tests for categorical and continuous variables, respectively. Logistic regression was used to identify factors associated with undergoing NET versus surgery first. This model was built in the generalized estimating equations framework and included an exchangeable correlation structure to account for the correlation of patients treated at the same facility. Adjustment factors were selected on the basis of clinical relevance and included age, year of diagnosis, gender, race and ethnicity, insurance type, comorbidity score, facility type and location, and clinical T- and N-category. Additional logistic regression models including interaction terms of clinical T-category or clinical N-category with year of diagnosis were conducted to determine if the association of clinical T-category or clinical N-category with the odds of undergoing NET changed over time.Only patients with complete cases were included in adjusted modeling, and sample sizes are included for all tables and figures. No adjustments were made for multiple comparisons. All statistical analyses were conducted in SAS, version 9.4 (SAS Institute, Cary NC).

    RESULTS

    We identified 283,481 patients ≥ 18 years of age with cT1–4c/cN0–3 and ER+, HER2− breast cancer. Of these, 10,935 (3.9%) received NET and 272,546 (96.1%) underwent upfront surgery (Fig. 1). Baseline characteristics including patient demographics, facility type, and comorbidities by treatment type are presented in (Table 1). Compared with patients undergoing surgery first, those receiving NET were more likely to have higher Charlson–Deyo comorbidity scores, present with more advanced disease, and be treated at academic or integrated network cancer centers. In addition, those receiving NET were more likely to have lobular histology (24.0% versus 19.4%, P < 0.001), be classified as cT3 or cT4 (5.2% versus 2.3%, P < 0.001), and have clinically positive axillary nodes (10.5% versus 5.2%, P < 0.001). Furthermore, they were more likely to have a mastectomy (45.5% versus 31.6%, P < 0.001), and less likely to receive chemotherapy (13.7% versus 16.7%, P < 0.001) or radiation (53.9% versus 64.9%, P < 0.001).The proportion of patients receiving NET varied during the three time periods. The use of NET increased significantly during the pandemic, rising from 2.3% in 2019 to 6.4% in 2020 (P < 0.001). This trend reversed in 2021 with a decline in NET utilization to 3.2% (Fig. 2) but remained higher than the prepandemic rate. After adjustment for clinical and demographic factors, the odds ratio (OR) for receiving NET were nearly three times as high in 2020 (OR 2.95, 95% CI: 2.67–3.26) and remained elevated in 2021 (OR 1.43, 95% CI: 1.31–1.56) compared with 2019 (Table 2). Notably, increased NET use in 2020 was consistent across all clinical T categories, including T1 tumors (Fig. 2).Logistic regression revealed that even after adjustment, patients receiving NET were more likely to be older (OR for age 70+ versus < 50: 1.15, 95% CI: 1.06–1.24, P = 0.001), have more comorbidities (OR for Charlson–Deyo 2+ versus 0: 1.14, 95% CI: 1.05–1.24, P = 0.002), and present with higher clinical T and N categories (e.g., OR for T4 versus T1: 2.92, 95% CI: 2.34–3.64, P < 0.001; OR for N3 versus N0: 2.00, 95% CI: 1.20–3.34, P = 0.008). Patients were also more likely to receive NET if they were treated at academic/research institutions (reference group; all other facility types had significantly lower odds) and if located in the Northeast (versus South: OR 1.41, 95% CI: 1.18–1.69, P < 0.001). There were no significant differences in NET use by race and ethnicity (P = 0.23) or insurance type (p = 0.46) (Table 2).Time from diagnosis to treatment was significantly shorter in the NET group (1.0 versus 1.4 months, P < 0.001). Among NET patients, the median time from start of endocrine to surgery was 44 days (IQR 28–70). BCS rates tended to be lower in the NET group overall, but the rates were similar in those with clinical T3 or T4 disease (Fig. 3).

    DISCUSSION

    Our retrospective analysis of the NCDB revealed that during the COVID-19 pandemic, NET rates for operable ER+ HER2− breast cancer nearly tripled, but following the pandemic, NET rates reverted towards prepandemic levels. This transitory increase in NET use reflects the ability to triage patients, identifying those who could be safely bridged with neoadjuvant therapy compared with those who required more urgent surgery such as individuals with triple negative, or HER2 amplified cancers if they were not candidates for neoadjuvant chemotherapy. Such unusual circumstances provided a unique opportunity to understand the outcomes associated with NET utilization, particularly in patients with earlier stage breast cancers (cT1–2) who would traditionally undergo upfront surgery.9Among patients with larger (> cT3 tumors and ER/PR+ HER2− disease, NET has been effective in tumor downsizing.4,10 In ACOSOG Z1031, more than half of postmenopausal women with stage II–III, ER+ breast cancers who were originally deemed ineligible for BCS were eligible after NET.11 Despite this, the use of NET has been low.12 During the pandemic, the use of NET increased significantly and while BCS rates tended to be lower in the NET group overall, the rates of BCS were equivalent to surgery upfront in those with T3 or T4 disease. Conversely, the lower rates for smaller size tumors were more likely owing to other factors such as comorbidities, patient preference, or pandemic-specific concerns given that these smaller tumors likely did not require downstaging prior to surgery from the onset. For example, some patients may have elected for mastectomy to avoid daily treatments required for postoperative radiation therapy and minimize potential COVID-19 exposure.The use of NET even in circumstances in which tumor downsizing was not required also revealed potentially new benefits, such as the ability to receive treatment sooner. Although the date of NET initiation as defined by the NCDB likely refers to the date it was prescribed, it is likely there was no delay in medication initiation, whereas surgery would typically be scheduled a couple weeks following the day of the consult. For patients who may have scheduling delays for the purpose of addressing unrelated health concerns or managing logistical challenges, NET may be a practical and attractive alternative to surgery first.The current study also demonstrates reduced use of chemotherapy in individuals who received NET. This can be partially explained by the fact that many patients with low-risk tumor biology do not necessarily benefit from chemotherapy and thus are offered ET alone.13,14 In addition, patients with many comorbidities limiting their ability to tolerate chemotherapy may also be offered ET monotherapy. However, it is also possible that treatment with NET could allow some patients to avoid chemotherapy.15 In a 2020 study comparing NAC and NET, a nodal pCR was achieved in 18% and 11% (P = 0.37), respectively.10 This suggests no significant difference in disease response between NAC and NET, and the argument for NET is likely even more compelling for strongly ER+ tumors. It is also especially interesting to note that patients receiving NET likely have only received a small portion of their total endocrine therapy, compared with NAC, in which all chemotherapy is usually given upfront. However, if patients achieve a pathologic complete response (pCR) after NET, their survival outcomes have been shown to resemble those who achieve a pCR after NAC.16Limitations to this study include its retrospective nature from a large database that can inherently suffer from selection bias and lack of specific treatment details, including decision-making factors. Time from diagnosis to treatment with NET may also be inaccurate owing to the inability to determine any lag time between the prescription being written and therapy initiation. For similar reasons, the total duration of endocrine therapy could not be ascertained, although NET duration could be estimated on the basis of the date of therapy initiation and date of surgery. Furthermore, patients who initiated NET in 2021 but underwent surgery in 2022 may not have been captured in this dataset, potentially underestimating BCS rates in this group. It is also impossible to accurately predict the impact of NET on long-term survival given the short time interval between the study population treatment and this analysis. This database is only inclusive of Commission on Cancer accredited institutions and thus is not necessarily representative of the experience at other institutions. Furthermore, the reason for surgical decision of BCS and mastectomy cannot be evaluated. Naturally, this database also does not capture the experience of patients who did not seek medical treatment during the pandemic.

    CONCLUSIONS

    This study demonstrates the implementation of NET during the pandemic. Longer-term analysis of this data will be needed to evaluate the durability of NET, including recurrence rates and survival. Future prospective trials may be better equipped to further define the potential role of NET in ER+/HER2− breast cancer and would be well-served to include other important factors, such as patient-reported outcomes and quality of life. Given that the understanding of tumor biology continues to evolve, it is likely that the use of NET will become more prevalent in selected populations, making it increasingly important to understand the implications.
    JPDr. Jennifer Plichta
    Leading Voice

    Dr. Jennifer Plichta

    Surgery · Breast Surgical Oncology
    Duke Medical Center
    jenniferp